# A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

> **NCT01004822** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 31 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** CVX-241
- **DRUG:** CVX-241
- **DRUG:** CVX-241
- **DRUG:** CVX-241
- **DRUG:** CVX-241
- **DRUG:** CVX-241
- **DRUG:** CVX-241
- **DRUG:** CVX-241

## Key facts

- **NCT ID:** NCT01004822
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004822, "A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01004822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*